Novo Nordisk says 80% of insured U.S. patients taking Wegovy pay less than  a month
Novo Nordisk says 80% of insured U.S. patients taking Wegovy pay less than  a month

Still life of Wegovy an injectable prescription weight reduction medication that has helped individuals with weight problems. It must be used with a weight reduction plan and bodily exercise. 

Michael Siluk | UCG | Getty Images

Novo Nordisk on Thursday mentioned 80% of U.S. patients with insurance coverage protection who take its extremely widespread weight reduction therapy Wegovy are paying less than $25 a month for the drug. 

The remarks counsel that many insured Americans do not should shoulder the complete value of a month-to-month package deal of Wegovy, which has a list price of round $1,350. It additionally comes as many U.S. well being insurers balk on the excessive value of Wegovy and different weight problems medicine whereas dropping them from their plans, at the same time as demand for these therapies soar nationwide and outpace provide. 

But Doug Langa, Novo Nordisk’s vice chairman for North America, mentioned on a third-quarter earnings name Thursday that almost all main well being plans and pharmacy profit managers are protecting Wegovy. 

Langa acknowledged that some employers are opting out of protection, however famous that the corporate total is seeing extra insurers choose in to cowl the weekly injection.

He estimated that about 50 million Americans with weight problems could possibly be eligible for Wegovy protection underneath their well being plans.

“Directionally, we’re on course and our focus might be persevering with on securing employer protection in addition to stronger entry for Americans total,” Langa mentioned throughout the name. 

However, the $25 out-of-pocket value will probably add up over time. Most patients should take Wegovy for a number of months to see – and maintain – important weight reduction. 

Wegovy, for instance, results in 15% weight reduction after 68 weeks, in keeping with medical trials on the drug.

The longer therapy length can also be one motive why some well being insurers are hesitant to cowl Wegovy and comparable weight reduction medicine, which generally work by mimicking a hormone produced within the intestine to suppress a particular person’s urge for food.

At roughly $1,000 per month on common for medicines which can be usually taken for months and even a 12 months, the medicine are straining insurers’ budgets.

But Novo Nordisk is hoping that new information demonstrating the guts well being advantages of Wegovy will put extra strain on insurers to cowl the remedy and comparable weight reduction therapies. 

A latest late-stage trial discovered that Wegovy diminished the chance of cardiovascular occasions like coronary heart assault and stroke by 20%. The outcomes counsel that Wegovy and comparable weight problems and diabetes medicines like these in improvement by Eli Lilly and others may have long-lasting well being advantages past shedding undesirable kilos.

Novo Nordisk CFO Karsten Munk Knudsen advised CNBC on Thursday that Wegovy may obtain expanded approval from the U.S. Food and Drug Administration as a therapy for lowering the chance of heart problems inside six months.

More than two in 5 adults have weight problems, in keeping with the National Institutes of Health.

About one in 11 adults have extreme weight problems.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *